• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Uncovering the biology of new immune-checkpoint molecule inhibitor and that impact for micro immune microenvironment

Research Project

Project/Area Number 22K16794
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 56030:Urology-related
Research InstitutionKeio University

Principal Investigator

Takamatsu Kimiharu  慶應義塾大学, 医学部(信濃町), 訪問研究員 (00649874)

Project Period (FY) 2022-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2023: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2022: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Keywords腎細胞癌 / 癌免疫微小環境 / TIGIT / 免疫チェックポイント阻害剤 / 腫瘍免疫微小環境 / 薬物療法 / 免疫チェックポイント分子 / LAG-3 / TLS
Outline of Research at the Start

LAG-3(lymphocyte activation gene 3)、TIM-3(lymphocyte activation gene 3)、TIGIT(T-cell immunoreceptor with Ig and ITIM domains)は、腎細胞癌を含む複数の固形癌で次世代免疫チェックポイント (IR: immune inhibitory receptor) 阻害剤の標的分子として注目される。申請者は、相互排他的な発現パターンを示す3分子(LAG-3, TIM-3, TIGIT)の分子生物学的背景を明らかにし、次世代IR阻害剤が腫瘍免疫微小環境に及ぼす影響を明らかにする。

Outline of Final Research Achievements

Cancer immuno therapy brought the great benefit to medical oncology, however some metastatic renal cell carcinoma (mRCC) patients showed primary resistance. In recent years, anti-LAG-3 antibody has been launched as a new treatment. We evaluated the clinical impact and the immune-microenvironment related with the other novel immune-chckpoint molecule, TIGIT in mRCC patients. The result showed high TIGIT expression mRCC patients showed good prognosis. High TIGIT expression was related with higher CD8+, FOXP3+, that showed exhausted T cell envrironment, with higher PD-1+, PD-L1+, that showed TIGIT is corelated with other immunecheckpoint molecules, and with higher CD68, CD163, that showed tumor associated immune-repressive environment. This clinical impact and TIGIT related immune-microenvironment characterics was varidated in the other clinical trial cohort.

Academic Significance and Societal Importance of the Research Achievements

TIGITは次世代癌免疫療法の標的分子として注目されるが、その免疫微小環境は不明である。今回我々はTIGIT発現の臨床的有用性に始まり、微小環境の特徴を評価し、かつそれを複数の大規模コホートで確認した。この結果はこれまでに腎細胞癌では報告されておらず、ここに学術的意義がある。
また、新規癌免疫療法は一定の効果を認める一方で、効果を認めない症例が一定数存在することが特徴である。治療有効または治療不応が予測される症例を選出するためにはその生物学的評価が重要となる。本研究成果は高額な新規癌免疫療法を適切な患者に届けることで、医療経済へのメリットにも繋がることが期待される。

Report

(3 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • Research Products

    (8 results)

All 2023 2022

All Journal Article (4 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 4 results,  Open Access: 2 results) Presentation (4 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Prognostic role of the innate immune signature CD163 and “eat me” signal calreticulin in clear cell renal cell carcinoma2023

    • Author(s)
      Anno Tadatsugu、Tanaka Nobuyuki、Takamatsu Kimiharu、Hakozaki Kyohei、Kufukihara Ryohei、Baba Yuto、Takeda Toshikazu、Matsumoto Kazuhiro、Morita Shinya、Kosaka Takeo、Mikami Shuji、Nishihara Hiroshi、Mizuno Ryuichi、Oya Mototsugu
    • Journal Title

      Cancer Immunology, Immunotherapy

      Volume: - Issue: 6 Pages: 1779-1788

    • DOI

      10.1007/s00262-023-03369-8

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer2023

    • Author(s)
      Izawa Mizuki、Tanaka Nobuyuki、Murakami Tetsushi、Anno Tadatsugu、Teranishi Yu、Takamatsu Kimiharu、Mikami Shuji、Kakimi Kazuhiro、Imamura Takeshi、Matsumoto Kazuhiro、Oya Mototsugu
    • Journal Title

      Laboratory Investigation

      Volume: 103 Issue: 4 Pages: 100040-100040

    • DOI

      10.1016/j.labinv.2022.100040

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma2022

    • Author(s)
      Kufukihara Ryohei、Tanaka Nobuyuki、Takamatsu Kimiharu、Niwa Naoya、Fukumoto Keishiro、Yasumizu Yota、Takeda Toshikazu、Matsumoto Kazuhiro、Morita Shinya、Kosaka Takeo、Aimono Eriko、Nishihara Hiroshi、Mizuno Ryuichi、Oya Mototsugu
    • Journal Title

      British Journal of Cancer

      Volume: 127 Issue: 6 Pages: 1133-1141

    • DOI

      10.1038/s41416-022-01895-3

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer2022

    • Author(s)
      Masuda Tsukasa、Tanaka Nobuyuki、Takamatsu Kimiharu、Hakozaki Kyohei、Takahashi Ryohei、Anno Tadatsugu、Kufukihara Ryohei、Shojo Kazunori、Mikami Shuji、Shinojima Toshiaki、Kakimi Kazuhiro、Tsunoda Tatsuhiko、Aimono Eriko、Nishihara Hiroshi、Mizuno Ryuichi、Oya Mototsugu
    • Journal Title

      Journal for ImmunoTherapy of Cancer

      Volume: 10 Issue: 3 Pages: 1-12

    • DOI

      10.1136/jitc-2021-003883

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Uncovering TIGIT related tumor immunology and clinical significance in renal cell carcinoma2023

    • Author(s)
      髙松公晴
    • Organizer
      第61回日本癌治療学会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Uncovering LAG-3 related tumor immunology in renal cell carcinoma and pan-cancer evaluation.2023

    • Author(s)
      Kimiharu Takamatsu
    • Organizer
      American Society of Clinical Oncology Annual meeting 2023
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 腎細胞癌と固形癌の次世代免疫チェックポイント分子LAG3と腫瘍免疫微小環境2022

    • Author(s)
      髙松公晴
    • Organizer
      第60回日本癌治療学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] 次世代免疫チェックポイント分子(LAG-3, TIM-3, TIGIT)による腎細胞がん新規分類の臨床的有用性2022

    • Author(s)
      髙松公晴
    • Organizer
      第109回日本泌尿器科学会総会
    • Related Report
      2022 Research-status Report

URL: 

Published: 2022-04-19   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi